Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease.
Linnebank M, Popp J, Smulders Y, Smith D, Semmler A, Farkas M, Kulic L, Cvetanovska G, Blom H, Stoffel-Wagner B, Kölsch H, Weller M, Jessen F.
Neurodegener Dis. 2010;7(6):373-8. doi: 10.1159/000309657. Epub 2010 Jun 3.
Similar articles
Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease.
Arlt S, Schwedhelm E, Kölsch H, Jahn H, Linnebank M, Smulders Y, Jessen F, Böger RH, Popp J.
J Alzheimers Dis. 2012;31(4):751-8. doi: 10.3233/JAD-2012-112138.
A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
Connelly PJ, Prentice NP, Cousland G, Bonham J.
Int J Geriatr Psychiatry. 2008 Feb;23(2):155-60.
Impacts of hyper-homocysteinemia and white matter hyper-intensity in Alzheimer's disease patients with normal creatinine: an MRI-based study with longitudinal follow-up.
Huang CW, Chang WN, Lui CC, Chen CF, Lu CH, Wang YL, Chen C, Juang YY, Lin YT, Tu MC, Chang CC.
Curr Alzheimer Res. 2010 Sep;7(6):527-33.
Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype.
Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr.
Neurology. 1998 Jan;50(1):164-8.
Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease.
Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, Shoji M.
Neurosci Lett. 1999 May 21;267(1):65-8.
Association of RFC1 A80G and MTHFR C677T polymorphisms with Alzheimer's disease.
Bi XH, Zhao HL, Zhang ZX, Zhang JW.
Neurobiol Aging. 2009 Oct;30(10):1601-7. doi: 10.1016/j.neurobiolaging.2007.12.010. Epub 2008 Feb 6.
Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study.
Kuusisto J, Koivisto K, Mykkänen L, Helkala EL, Vanhanen M, Hänninen T, Kervinen K, Kesäniemi YA, Riekkinen PJ, Laakso M.
BMJ. 1997 Oct 25;315(7115):1045-9.
Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
Biol Psychiatry. 2004 Nov 1;56(9):670-6.
S-adenosylhomocysteine and the ratio of S-adenosylmethionine to S-adenosylhomocysteine are not related to folate, cobalamin and vitamin B6 concentrations.
Becker A, Smulders YM, Teerlink T, Struys EA, de Meer K, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD.
Eur J Clin Invest. 2003 Jan;33(1):17-25.
Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease.
Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW.
Biol Psychiatry. 1999 Feb 15;45(4):422-5.
The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease.
Selley ML, Close DR, Stern SE.
Neurobiol Aging. 2002 May-Jun;23(3):383-8.
A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease.
Selley ML.
Neurobiol Aging. 2007 Dec;28(12):1834-9. Epub 2006 Sep 25.
Methylenetetrahydrofolate reductase gene and risk of Alzheimer's disease in Koreans.
Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Shin HY, Yoon JS.
Int J Geriatr Psychiatry. 2008 May;23(5):454-9.
Association of complement factor H Y402H gene polymorphism with Alzheimer's disease.
Zetterberg M, Landgren S, Andersson ME, Palmér MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H.
Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):720-6. doi: 10.1002/ajmg.b.30668.
Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
Lasser RA, Dukoff R, Levy J, Levin R, Lehtimäki T, Seubert P, Sunderland T.
Int J Geriatr Psychiatry. 1998 Nov;13(11):767-74.
The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers.
Martínez MF, Martín XE, Alcelay LG, Flores JC, Valiente JM, Juanbeltz BI, Beldarraín MA, López JM, Gonzalez-Fernández MC, Salazar AM, Gandarias RB, Borda SI, Marqués NO, Amillano MB, Zabaleta MC, de Pancorbo MM.
BMC Neurosci. 2009 Sep 30;10:125. doi: 10.1186/1471-2202-10-125.
Alzheimer's disease and total plasma aminothiols.
McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, Regland B.
Biol Psychiatry. 2003 Feb 1;53(3):254-60.
Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls.
Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T.
J Alzheimers Dis. 2009;18(2):331-7. doi: 10.3233/JAD-2009-1146.
[Plasma, red cell, and cerebrospinal fluid folate in Alzheimer's disease].
Abalan F, Zittoun J, Boutami C, Dugrais G, Manciet G, Decamps A, Antoniol B.
Encephale. 1996 Nov-Dec;22(6):430-4. French.
Filters: Manage Filters